Organized primarily around adverse reactions of the human body to stress, Sentia is tackling bringing to use condition decades of research already undertaken to enable development of drugs that block the action of corticotropin releasing factor (CRF) and urocortins, the main mediators of the bodyâs response to stress. Present emphasis in addressing most disease states is to treat for symptoms - effectively not taking into account the involvement of chronic stress. The latter is understood to cause important physiological mechanisms in the human body to become imbalanced, leading to initiation or exacerbation of multiple diseases. Sentia is tackling means whereby to harmonize and rebalance the physiology using a new generation of drug candidates called astressins that have high efficacy and sustained effects
